Sugi Predict

Sugi Predict / Compounds / SCHEMBL6117

SCHEMBL6117

SCHEMBL6117

COc1cccc(F)c1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 4/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ L3MBTL1 Q9Y468 3/20 0.47
▸ MAPT P10636 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ CTDSP1 Q9GZU7 1/20 0.46
▸ KMT2A Q03164 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ PRMT1 Q99873 1/20 0.42
▸ GAA P10253 2/20 0.42
▸ PKM P14618 1/20 0.42
▸ NFE2L2 Q16236 1/20 0.42
▸ HSPB1 P04792 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ CDK2 P24941 1/20 0.40
▸ GFER P55789 1/20 0.40
▸ TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30297160 1.00 TDP1 (0.53) TDP1ALDH1A1L3MBTL1MAPTSMN1; SMN2
SCHEMBL1341322 0.87 L3MBTL1 (0.46) TDP1ALDH1A1L3MBTL1MAPTSMN1; SMN2
SCHEMBL19189611 0.87 L3MBTL1 (0.45) TDP1ALDH1A1L3MBTL1MAPTSMN1; SMN2
SCHEMBL14596230 0.86 L3MBTL1 (0.44) TDP1ALDH1A1L3MBTL1MAPTSMN1; SMN2
SCHEMBL13066856 0.86 L3MBTL1 (0.44) TDP1ALDH1A1L3MBTL1MAPTSMN1; SMN2
SCHEMBL1961457 0.86 TDP1 (0.63) TDP1ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL25293041 0.83 MAPT (0.44) TDP1ALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL29791297 0.82 MAPT (0.43) TDP1ALDH1A1L3MBTL1MAPTSMN1; SMN2
SCHEMBL17165866 0.82 MAPT (0.43) TDP1ALDH1A1L3MBTL1MAPTSMN1; SMN2
SCHEMBL27693986 0.82 L3MBTL1 (0.47) TDP1ALDH1A1L3MBTL1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110294721-A The synthesis technology of 1- acetyl group -4- [3- (methyl oxygroup) -4- nitrobenzophenone] piperazine 安庆缘启医药科技有限公司 2019-10-01 — — CN claimed
CN-106883216-A A kind of uncommon preparation method for Buddhist nun difficult to understand 张家港威胜生物医药有限公司 2017-06-23 — — CN claimed
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 — — WO disclosed
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS INTERLINE THERAPEUTICS INC (US) 2025-11-13 — — US disclosed
US-12384777-B2 Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts Tay Therapeutics Limited (GB) 2025-08-12 — — US disclosed
US-12338226-B2 Substituted benzodiazoles and use thereof in therapy THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) 2025-06-24 — — US disclosed
US-20250171427-A1 THERAPEUTIC COMPOUNDS SANOFI (FR) 2025-05-29 — — US disclosed
US-20250109139-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) 2025-04-03 — — US disclosed
CN-119698416-A Imidazo (1, 2-A) pyridine derivatives as RIPK2 inhibitors 英特莱治疗公司 2025-03-25 — — CN disclosed
EP-4524139-A1 IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE Shanghai Simr Biotechnology Co., Ltd. (CN) 2025-03-19 — — EP disclosed
WO-2025010314-A1 UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-01-09 — — WO disclosed
EP-1846400-A2 TRICYCLIC DELTA-OPIOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-24 — — EP disclosed
EP-1833826-A2 TRICYCLIC DELTA-OPIOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-09-19 — — EP disclosed
CN-101037380-A Preparation method of 2,3-Difluoro-5-Bromophenol SHANGHAI KANGPENG CHEMICAL CO (CN) 2007-09-19 — — CN disclosed
WO-2006074388-A2 TRICYCLIC δ-OPIOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-13 — — WO disclosed
US-20060148823-A1 Tricyclic delta-opioid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 — — US disclosed
WO-2006069276-A2 TRICYCLIC ō-OPIOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-29 — — WO disclosed
US-20060135763-A1 Tricyclic delta-opioid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-22 — — US disclosed
CN-1699363-A Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2005-11-23 — — CN disclosed
CN-1483024-A Vla-4 inhibitors ��һ��������ҩ��ʽ���� 2004-03-17 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148823-A1 Tricyclic delta-opioid modulators OPRD1, OPRK1, OPRL1 TDP1 3925/4885ALDH1A1 1302/4885L3MBTL1 2619/4885
US-20250109139-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF PARK7, HADH, BDNF TDP1 1023/4885ALDH1A1 1460/4885L3MBTL1 3374/4885
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS RIPK2, RIPK1, RIPK4 TDP1 938/4885ALDH1A1 3792/4885L3MBTL1 3544/4885
US-20060135763-A1 Tricyclic delta-opioid modulators OPRD1, OPRK1, OPRL1 TDP1 3925/4885ALDH1A1 1302/4885L3MBTL1 2619/4885
US-20250171427-A1 THERAPEUTIC COMPOUNDS IL17A, IL2, IL36G TDP1 3192/4885ALDH1A1 449/4885L3MBTL1 4731/4885
US-12384777-B2 Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts TPMT, IL5, P2RY6 TDP1 1945/4885ALDH1A1 1800/4885L3MBTL1 4198/4885
US-12338226-B2 Substituted benzodiazoles and use thereof in therapy XDH, CYP11B2, CYP4X1 TDP1 1726/4885ALDH1A1 274/4885L3MBTL1 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.